Novo Nordisk Shares Surge Following Aggressive Pricing Move in India

Investors have responded with strong approval to Novo Nordisk’s latest strategic maneuver in the Indian pharmaceutical market. The Danish pharmaceutical giant implemented a substantial price reduction for its weight-loss medication Wegovy, triggering a notable share price increase of approximately seven percent. This decisive action intensifies the company’s competitive stance against primary rival Eli Lilly in a critical growth market.

Effective immediately, the entry-level dose of Wegovy will be available in India for approximately €115 per month, representing a sharp 37 percent decrease from the previous cost of nearly €185. Market analysts view this timing as strategically significant, with the drug’s patent protection scheduled to expire in March 2026. Generic manufacturers are Read more...